DBV Technologies' American depositary receipts fell after the company said its cash would likely run out after next month. The stock was down 10% at $4.48 in premarket trading on Monday. Shares ...

Clinical-stage biopharmaceutical company DBV Technologies (NASDAQ:DBVT) announced a financing of up to $306.9M (€284.5M), including gross proceeds of $125.5M (€116.3M) to be received upon ...

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of ...

Shares of DBV Technologies (DBVT) are moving lower after the company a “substantial doubt regarding its ability to continue as a going concern.” When reporting unaudited results for 2024 ...

American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million. The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning.

Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 ...

DBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrants DBV sufficiently funded through the expected Biologics ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other ...